Abstract
In November 2014, the Japanese government enacted the Act on the Safety of Regenerative Medicine (ASRM) to regulate the use of stem cells and cell-based products within the context of clinical research and medical practice (Konomi et al., 2015). The government introduced this law as part of a wider framework to promote the clinical translation of stem cells, particularly induced pluripotent stem cells (iPSCs), for which Shinya Yamanaka received the Nobel Prize for Physiology and Medicine in 2012.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
